H.C. Wainwright lowered the firm’s price target on AnaptysBio (ANAB) to $52 from $55 and keeps a Buy rating on the shares following the Q3 report. The firm says that despite Lilly discontinuing peresolimab, it remains confident in AnaptysBio’s Phase 2 rheumatoid arthritis data expected in February 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB: